BioSpace News Archive

Following distribution agreements for Russia, Ecuador, Panama, Romania and Moldova, PreCheck’s eleven combined distribution territories have an aggregate population of 298 million

Aptorum Group Limited provides an update on the Company’s operations in light of the recent declaration of the coronavirus outbreak as a pandemic declared by the World Health Organisation on March 11, 2020.

Promethera ® Announces Changes in Management Team

Aptorum Group Limited announced that it is initiating an additional research and development project targeting the coronavirus group and has completed initial screening under the Smart-ACT™ platform, a repurposed and new drug discovery platform, to select, out of more than 2,600 approved small drug molecules, at least 3 potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19.

Fapon Biotech Inc., a global leading IVD raw materials and one-stop solutions company offering products and technologies to enable the rapid development and production of reagents, initiated a global donation to give a total of 3 million PCR test components to IVD partners.

Saama Technologies, Inc. (“Saama”), the #1 AI clinical analytics platform company, announced today that it will contribute its AI-powered Life Science Analytics Cloud (LSAC) technology platform to establish the EndPandemic National Data Consortium.

Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced the grant of inducement equity awards to two newly hired employees.

One of the largest health systems in the U.S. rapidly deploys digital health solution to combat pandemic.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that it has submitted an Investigational New Drug (IND) application to South Korea’s Ministry of Food and Drug Safety (MFDS), to evaluate the safety and efficacy of TJM2 in treating cytokine storm (CS) in severe and critically ill patients caused by the coronavirus disease (COVID-19).

Dr. Eric von Hofe, PhD, Chief Scientific Officer of NuGenerex Immuno-Oncology to Speak on the Race to Develop a SARS-CoV-2 Vaccine Monday March 30, 2020 at 3 PM